Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATF4 | P18848 | 10/20 | 0.78 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | SENP2 | Q9HC62 | 1/20 | 0.45 |
| ▸ | SENP1 | Q9P0U3 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22614436 | 0.92 | ATF4 (0.86) | ATF4NPC1RAB9ATSHRNPSR1 | |
| SCHEMBL19555369 | 0.91 | ATF4 (0.83) | ATF4NPC1RAB9ATSHRNPSR1 | |
| SCHEMBL19569281 | 0.90 | ATF4 (0.94) | ATF4NPC1RAB9ATSHRNPSR1 | |
| Hydrochloric Acid SCHEMBL20610394 | 0.89 | ATF4 (0.81) | ATF4NPC1RAB9ATSHRNPSR1 | |
| SCHEMBL19569398 | 0.88 | ATF4 (1.00) | ATF4NPC1RAB9ATSHRNPSR1 | |
| SCHEMBL22656718 | 0.87 | ATF4 (1.00) | ATF4NPC1RAB9ATSHRNPSR1 | |
| SCHEMBL19555380 | 0.86 | ATF4 (0.57) | ATF4ALDH1A1 | |
| SCHEMBL21618352 | 0.85 | ATF4 (0.80) | ATF4NPC1RAB9ATSHRNPSR1 | |
| SCHEMBL19569505 | 0.85 | ATF4 (0.84) | ATF4NPC1RAB9ATSHRNPSR1 | |
| SCHEMBL20974142 | 0.84 | ATF4 (1.00) | ATF4NPC1RAB9ATSHRNPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210093619-A1 | Chemical Compounds as ATF-4 Pathway Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-01 | — | — | US | disclosed |
| US-20210093619-A1 | Chemical Compounds as ATF-4 Pathway Inhibitors | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2021-04-01 | — | — | US | disclosed |
| EP-3634952-A1 | CHEMICAL COMPOUNDS AS ATF4 PATHWAY INHIBITORS | GlaxoSmithKline Intellectual Property Development Limited (GB) | 2020-04-15 | — | — | EP | disclosed |
| WO-2018225093-A1 | CHEMICAL COMPOUNDS AS ATF4 PATHWAY INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-12-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210093619-A1 | Chemical Compounds as ATF-4 Pathway Inhibitors | ATF4, ATF1, XBP1 | ATF4 1/4885NPC1 514/4885RAB9A 3165/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.